The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists
Published version of a preprint
Abstract
Abstract In a recent report in Science Signaling (DOI: 10.1126/scisignal.aaz3140), it was suggested that low intrinsic agonism, and not biased agonism, leads to an improvement in the separation of potency in opioid-induced respiratory suppression versus antinociception. Although many of the compounds that were tested have been shown to display G protein signaling bias in prior publications, the authors conclude that since they cannot detect biased agonism in their cellular signaling studies the compounds are therefore not biased agonists. Rather, they conclude that it is low intrinsic efficacy that leads to the therapeutic window improvement. Intrinsic efficacy is the extent to which an agonist can stimulate a G protein-coupled receptor (GPCR) response in a system, while biased agonism takes into consideration not only intrinsic efficacy, but also potency of an agonist in an assay. Herein, we have re-analyzed the data presented in the published work (DOI: 10.1126/scisignal.aaz3140) (including the recent Erratum: DOI: 10.1126/scisignal.abf9803) to derive intrinsic efficacy and bias factors as ΔΔlog(τ/K A ) and ΔΔlog(Emax/EC 50 ). Based on this reanalysis, the data support the conclusion that biased agonism, favoring G protein signaling, was observed. Moreover, a conservation of rank order intrinsic efficacy was not observed upon comparing responses in each assay, further suggesting that multiple active receptor states were present. These observations agree with prior studies wherein oliceridine, PZM21 and SR-17018 were first described as biased agonists with improvement in antinociception over respiratory suppression in mice. Therefore, the data in the Science Signaling manuscript does provide strong corroborating evidence that G protein signaling bias may be a means to improve opioid analgesia while avoiding certain undesirable side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE ROLE OF RECEPTOR KINASES AND ARRESTINS IN G PROTEIN–COUPLED RECEPTOR REGULATION
Krupnick, J. G., & Benovic, J. (1998) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.289 · Cited by 1,116
Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2
Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077
Self-citationStructure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D. G., Corder, G. F., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 988
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence
Bohn, L., Gainetdinov, R. R., Lin, F., Lefkowitz, R. J., & Caron, M. G. (2000) · Nature · doi:10.1038/35047086 · Cited by 930
Self-citationSignalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
Morphine Side Effects in β-Arrestin 2 Knockout Mice
Raehal, K. M., Walker, J. K. L., & Bohn, L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 657
Self-citationDeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 1×
“The study by Schmid et al., 2017, addressed this question by generating a series of structurally related MOR agonists that spanned a spectrum of both bias and intrinsic efficacy 8.”
BackgroundBerg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.94 · Cited by 512
Zhang, J., Ferguson, S. S. G., Barak, L. S., Bodduluri, S. R., Laporte, S. A., Law, P., & Caron, M. G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.7157 · Cited by 505
The two-state model of receptor activation
Leff, P. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88989-0 · Cited by 488
A Simple Method for Quantifying Functional Selectivity and Agonist Bias
Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200111m · Cited by 484
Huang, P., Kehner, G. B., Cowan, A., & Liu‐Chen, L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29586-0 · Cited by 344
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336
The role of kinetic context in apparent biased agonism at GPCRs
Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10842 · Cited by 328
Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., Le Rouzic, V., Grinnell, S. G., Subrath, J. J., Warner, E., Kalra, S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00748 · Cited by 323
Lewis, J. W. (1985) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(85)90067-5 · Cited by 239
Selley, D. E., Sim, L. J., Xiao, R., Liu, Q., & Childers, S. R. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.1.87 · Cited by 207
A three-state receptor model of agonist action
Leff, P., Scaramellini, C., Law, C., & McKechnie, K. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01105-x · Cited by 196
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor
Gillis, A., Kliewer, A., Kelly, E., Henderson, G., Christie, M. J., Schulz, S., & Canals, M. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.009 · Cited by 169
Hill, R. W., Disney, A., Conibear, A. E., Sutcliffe, K. J., Dewey, W. L., Husbands, S. M., Bailey, C. P., Kelly, E., & Henderson, G. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14224 · Cited by 167
Faouzi, A., Varga, B. R., & Majumdar, S. (2020) · Molecules · doi:10.3390/molecules25184257 · Cited by 156
Efficacy and ligand bias at the μ‐opioid receptor
Kelly, E. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12222 · Cited by 139
G-protein–gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids
Montandon, G., Ren, J. T., Victoria, N. C., Liu, H., Wickman, K., Greer, J. J., & Horner, R. L. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000984 · Cited by 135
Naloxone Reversal of Buprenorphine-induced Respiratory Depression
van Dorp, E., Yassen, A., Sarton, E. Y., Romberg, R. R., Olofsen, E., Teppema, L. J., Danhof, M., & Dahan, A. (2006) · Anesthesiology · doi:10.1097/00000542-200607000-00012 · Cited by 129
Miess, E., Gondin, A. B., Yousuf, A., Steinborn, R., Mößlein, N., Yang, Y., Göldner, M., Ruland, J. G., Bünemann, M., Krasel, C., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aas9609 · Cited by 124
Griffin, M. T., Figueroa, K. W., Liller, S., & Ehlert, F. J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120857 · Cited by 123
Buprenorphine: differential interaction with opiate receptor subtypes in vivo.
Sadée, W., Rosenbaum, J. S., & Herz, A. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33306-9 · Cited by 118
The clinical analgesic efficacy of buprenorphine
Raffa, R. B., Haidery, M., Huang, H.-M., Kalladeen, K., Lockstein, D. E., Ono, H., Shope, M. J., Sowunmi, O. A., Tran, J. K., & Pergolizzi, J. V. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12196 · Cited by 105
Schneider, S., Provasi, D., & Filizola, M. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00948 · Cited by 95
Biased Signaling of the Mu Opioid Receptor Revealed in Native Neurons
Ehrlich, A. T., Semache, M., Gross, F., Fonte, D. F. D., Runtz, L., Colley, C., Mezni, A., Gouill, C. L., Lukasheva, V., Hogue, M., et al. (2019) · iScience · doi:10.1016/j.isci.2019.03.011 · Cited by 87
Molecular insights into the biased signaling mechanism of the μ-opioid receptor
Cong, X., Maurel, D., Déméné, H., Vasiliauskaité-Brooks, I., Hagelberger, J., Peysson, F., Saint‐Paul, J., Golebiowski, J., Granier, S., & Sounier, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.033 · Cited by 77
A Practical Guide to Approaching Biased Agonism at G Protein Coupled Receptors
Gundry, J. N., Glenn, R. A., Alagesan, P., & Rajagopal, S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00017 · Cited by 74
Gillis, A., Sreenivasan, V., & Christie, M. J. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.119214 · Cited by 73
P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception
Brown, S. M., Campbell, S. D., Crafford, A., Regina, K. J., Holtzman, M. J., & Kharasch, E. D. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193433 · Cited by 72
Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71
Self-citationKuo, A., Wyse, B. D., Meutermans, W. D. F., & Smith, M. T. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12696 · Cited by 65
Molecular mechanisms of fentanyl mediated β-arrestin biased signaling
de Waal, P. W., Shi, J., You, E., Wang, X., Melcher, K., Jiang, Y., Xu, H. E., & Dickson, B. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007394 · Cited by 58
Warner, N. S., Warner, M. A., Cunningham, J. L., Gazelka, H. M., Hooten, W. M., Kolla, B. P., & Warner, D. O. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.10.007 · Cited by 56
Pharmacological Onomastics: What's in a name?
Kenakin, T. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707407 · Cited by 50
Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
Lambert, D. G., & Calò, G. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.09.021 · Cited by 47
Ayad, S. S., Demitrack, M. A., Burt, D. A., Michalsky, C., Wase, L., Fossler, M. J., & Khanna, A. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00936-0 · Cited by 44
Tran, J. A., Chang, A. L., Matsui, M., & Ehlert, F. J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.051276 · Cited by 40
A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor
Dekan, Z., Sianati, S., Yousuf, A., Sutcliffe, K. J., Gillis, A., Mallet, C., Singh, P., Jin, A., Wang, A. M., Mohammadi, S. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908662116 · Cited by 38
Bergese, S. D., Berkowitz, R., Rider, P. F., Ladouceur, M., Griffith, S. C., Vasi, A. S., Cochrane, K., Wase, L., Demitrack, M. A., & Habib, A. S. (2020) · Pain Research and Management · doi:10.1155/2020/7492865 · Cited by 36
Podlewska, S., Bugno, R., Kudla, L., Bojarski, A. J., & Przewłocki, R. (2020) · Molecules · doi:10.3390/molecules25204636 · Cited by 31
Functional studies cast light on receptor states
Ehlert, F. J. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.05.008 · Cited by 30
[35S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord
Madia, P. A., Navani, D. M., & Yoburn, B. C. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.11.001 · Cited by 22
Janković, S. M., Milovanović, D., Mitrović, M., & Đukić-Dejanović, S. (1996) · PubMed · Cited by 13
(2021) · Science Signaling · doi:10.1126/scisignal.abf9803 · Cited by 2
Research works printed but not linked: 2
- Huang P., 2001, J. Pharmacol. Exp. Ther., 297, 688
- Sadee W., 1982, J. Pharmacol. Exp. Ther., 223, 157
Metadata
- Authors
- Stahl, E. L., & Bohn, L. M.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-09-01
- Volume
- 61
- Issue
- 18
- Pages
- 1923-1935
- ISSN
- 0006-2960
- 1520-4995
- Cited by
- 55
- References
- 51
- Language
- en
- Licence
- Funders
- National Institute on Drug Abuse (DA033073, DA038964)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.